TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9488190
Drug: International Nifedipine
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: International Nifedipine Trial of Antiatherosclerotic Therapy (INTACT)
Study: 25902885
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (rosuvastatin 5 mg/day + ezetimibe 10 mg/day)
Study: 25902885
Drug: Monotherapy (rosuvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy (rosuvastatin 5 mg/day)
Study: 24861411
Drug: 0.12% chlorhexidine
Normalized name: CHLORHEXIDINE GLUCONATE 1.2 [iU] in 1 mL BUCCAL MOUTHWASH [0.12% Chlorhexidine Gluconate Oral Rinse]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.12% chlorhexidine + 0.05% cetylpyridinium chloride (CPC) solution
Study: 20724576
Drug: CHOP-like chemotherapy
Normalized name: insulin-like growth factor 2
DrugBank: Insulin-like growth factor II (DB14472)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHOP-like chemotherapy without rituximab
Study: 7899391
Drug: Pefloxacin (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pefloxacin (800 mg + placebo)
Study: 24206747
Drug: 2 L
Normalized name: H-2 locus
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 L of PEG3350e with 15 mg bisacodyl
Study: 20643762
Drug: Oral cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cyclophosphamide (CYC)
Study: 29972884
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg acetylsalicylic acid
Study: 14764947
Drug: Fructose infusion
Normalized name: Fructose
DrugBank: Fructose (DB04173)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fructose infusion during ITT
Study: 9026840
Drug: bezafibrate (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: bezafibrate (400 mg/day)
Study: 6706275
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of codeine and paracetamol
Study: 6706275
Drug: Rectal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rectal administration of codeine and paracetamol
Study: 12870368
Drug: Cefuroxime axetil
Normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefuroxime axetil 500 mg twice daily for 10 days
Study: 15298070
Drug: Tricyclic antidepressants
Normalized name: TRICYCLIC ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tricyclic antidepressants (TCAs)
Study: 8694150
Drug: Sodium citrate
Normalized name: Sodium Citrate
DrugBank: Sodium nitrate (DB15952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium citrate 0.3 M, 30 ml (group C)
Study: 8694150
Drug: Metoclopramide 10
Normalized name: metoclopramide 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide 10 mg IV + Sodium citrate (group MC)
Study: 8694150
Drug: Sodium citrate
Normalized name: Sodium Citrate
DrugBank: Sodium nitrate (DB15952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium citrate + Ranitidine 50 mg IV (group RC)
Study: 8694150
Drug: Sodium citrate
Normalized name: Sodium Citrate
DrugBank: Sodium nitrate (DB15952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium citrate + Omeprazole 40 mg IV (group OC)
Study: 2868744
Drug: Bucindolol (50,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bucindolol (50, 100, 200 and 400 mg)
Study: 6142007
Drug: Pindolol (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pindolol (10 mg)
Study: 202141
Drug: Propranolol (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (160 mg)
Study: 29673735
Drug: Triple drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple drug therapy (TDT) with albendazole (400 mg), pyrantel pamoate (20 mg/kg), and oxantel pamoate
Study: 16565792
Drug: Heparin for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin for 24 hours combined with 325 mg acetyl‐acetic acid (Group A)
Study: 16565792
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg ticlopidine twice a day combined with 325 mg acetyl‐acetic acid (Group B)
Study: 8970140
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg ferric sodium citrate
Study: 8970140
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg ferric sodium citrate with 200 mg ascorbic acid
Study: 8970140
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg ferric sodium citrate without vitamin C
Study: 22464674
Drug: Oral bacterial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral bacterial lysate
Study: 6204149
Drug: Slow release
Normalized name: Slow Release Iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow release potassium tablets (64 mmol/day)
Study: 20927038
Drug: Raloxifene 120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raloxifene 120 mg/day
Study: 3107602
Drug: lysine acetyl
Normalized name: Lysine acetylcysteinate
DrugBank: Nacystelyn (DB17839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: lysine acetyl salicylate (LAS) 13 mg kg‐1 i.v. 3 min before suxamethonium
Study: 3107602
Drug: atracurium 0.09
Approvals — FDA: no, EMA: no, PMDA: no
Description: atracurium 0.09 mg kg‐1
Study: 26589253
Drug: Dapagliflozin 5
Normalized name: dapagliflozin 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapagliflozin 5 mg
Study: 18026714
Drug: Oral N-acetylcysteine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral N-acetylcysteine (NAC)
Study: 20950456
Drug: New DTPw-HBV/Hib
Approvals — FDA: no, EMA: no, PMDA: no
Description: New DTPw-HBV/Hib vaccine
Study: 18242706
Drug: Treatment of
Normalized name: DRUGS FOR TREATMENT OF LEPRA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment of unruptured aneurysms
Study: 8757567
Drug: r‐HuEPO therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: r‐HuEPO therapy (20 U/kg body weight, subcutaneously, three times a week for 6 weeks)
Study: 18496338
Drug: Control (sham
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (sham treatment)
Study: 8757567
Drug: r‐HuEPO therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: r‐HuEPO therapy
Study: 2864775
Drug: Timolol and
Normalized name: timolol and thiazides
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timolol and aceclidine combination
Study: 31317553
Drug: Robotic-assisted therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Robotic-assisted therapy with bilateral practice (RTBP)
Study: 20351325
Drug: 80 IU/m(2)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 IU/m(2) of pegylated arginine deiminase (ADI) weekly for up to 6 months
Study: 17506785
Drug: Dabigatran etexilate
Normalized name: Dabigatran etexilate
DrugBank: Dabigatran etexilate (DB06695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dabigatran etexilate (10-400 mg single doses or 50-400 mg three times daily for 6 days)
Study: 15474697
Drug: Statin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin treatment started at least 3 days before the procedure
Study: 11486456
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with 1% lanoconazole cream and 10% urea ointment (Pastaron)
Study: 9743849
Drug: Propofol 3
Normalized name: fospropofol 35 mg/mL intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 3 mg
Study: 9743849
Drug: Propofol 9
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol 9 mg
Study: 9743849
Drug: Propofol 27
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol 27 mg
Study: 2899062
Drug: Ro 16-8714
Normalized name: RO-5045337
DrugBank: RO-5045337 (DB14793)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ro 16-8714 (0.17 mg/kg fat free mass)
Study: 24044216
Drug: Peginterferon alpha‐2a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peginterferon alpha‐2a combined with entecavir for 12 weeks, then Peginterferon alpha‐2a monotherapy for 36 weeks (Group C)
Study: 20307262
Drug: SCION‐PAIN program
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCION‐PAIN program (additional to standard pain treatment)
Study: 17951035
Drug: HHQ-free coffee
Normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HHQ-free coffee (zero-dose)
Study: 17951035
Drug: HHQ-free coffee
Normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HHQ-free coffee (middle-dose)
Study: 17951035
Drug: HHQ-free coffee
Normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HHQ-free coffee (high-dose)
Study: 16750285
Drug: Alveolar vaccination
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alveolar vaccination (controlled inhalation of Pneumovax)
Study: 16750285
Drug: Bronchial vaccination
Normalized name: Bronchitol
DrugBank: Mannitol (DB00742)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bronchial vaccination (controlled inhalation of Pneumovax)
Study: 16750285
Drug: Standard intramuscular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard intramuscular vaccination (control group)
Study: 2127537
Drug: Low-dose amiodarone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose amiodarone with low-dose flecainide
Study: 21341932
Drug: Fast track
Normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fast track diagnosis and treatment program for CRC
Study: 17996561
Drug: Candesartan (titrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan (titrated to a target of 32 mg once daily)
Study: 31512072
Drug: UV irradiated
Normalized name: Influenza B virus B/Brisbane/60/2008 antigen (UV, formaldehyde inactivated)
Approvals — FDA: no, EMA: no, PMDA: no
Description: UV irradiated surface-treated implants
Study: 31512072
Drug: Original surface
Approvals — FDA: no, EMA: no, PMDA: no
Description: Original surface implants (control)
Study: 28921814
Drug: Nabilone 2
Normalized name: nabilone 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nabilone 2 mg/day for 10 weeks
Study: 25528200
Drug: Carvedilol 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol 2.5 mg
Study: 25528200
Drug: Carvedilol 5
Normalized name: carvedilol 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol 5 mg
Study: 24798657
Drug: Carvedilol 20
Normalized name: Carvedilol 20mg Oral capsule, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol 20 mg
Study: 25528200
Drug: Carvedilol (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol (all doses)
Study: 19296355
Drug: Potentially effective
Normalized name: Potentilla discolor whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potentially effective treatments
Study: 340005
Drug: Subcutaneous saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous saline
Study: 16675939
Drug: Remifentanil 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil 0.25 mg kg(‐1) h(‐1)
Study: 16675939
Drug: Fentanyl 2‐3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 2‐3 mg kg(‐1) h(‐1)
Study: 15251635
Drug: Insulin-glucose infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin-glucose infusion for at least 24 hours followed by long-term subcutaneous insulin treatment
Study: 15251635
Drug: Insulin treatment
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin treatment in patients without prior insulin treatment
Study: 11744471
Drug: Finasteride (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Finasteride (5 mg daily for 3 months)
Study: 2499466
Drug: Multiple insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multiple insulin injections (MII)
Study: 31366262
Drug: Alogliptin (once-daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alogliptin (once-daily DPP-4i)
Study: 31366262
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (Alogliptin and Trelagliptin)
Study: 27510533
Drug: Nonalkalized cocoa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonalkalized cocoa mixture containing 0.6 mg epicatechin, 0.2 mg catechin, and 2.9 mg monomer-decamer procyanidins/kg body weight
Study: 27510533
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of epicatechin and nonalkalized cocoa mixture containing 1.6 mg epicatechin/kg body weight
Study: 24476418
Drug: Inhaled tobramycin
Normalized name: tobramycin Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled tobramycin with concomitant azithromycin
Study: 22626813
Drug: I-gel prewarmed
Normalized name: iobenguane I-131
Approvals — FDA: no, EMA: no, PMDA: no
Description: I-gel prewarmed to 37 °C
Study: 22626813
Drug: I-gel kept
Normalized name: iobenguane I-131
Approvals — FDA: no, EMA: no, PMDA: no
Description: I-gel kept at room temperature (approximately 20 °C)
Study: 20724949
Drug: Oral L-arginine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral L-arginine supplementation (0.1, 0.2, and 0.4 g/kg)
Study: 20724949
Drug: Oral L-arginine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral L-arginine supplementation
Study: 29483030
Drug: Intranasal live
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal live attenuated influenza vaccine (LAIV)
Study: 18597900
Drug: Intramuscular trivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular trivalent inactivated influenza vaccine (TIV)
Study: 16888425
Drug: Sildenafil citrate
Normalized name: Sildenafil Citrate
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sildenafil citrate (50 mg)
Study: 11487753
Drug: High iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: High iron formula (20.7 mg iron/L)
Study: 11487753
Drug: Normal iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal iron formula (13.4 mg iron/L)
Study: 8701624
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g cefotiam
Study: 31128285
Drug: No antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antibiotic treatment
Study: 31296251
Drug: Placebo (0.9%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0.9% saline) administered in identical volume and manner as the treatment group
Study: 28596642
Drug: Saxagliptin 5
Normalized name: sAXagliptin 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saxagliptin 5 mg daily for 3 months
Study: 19108791
Drug: Atenolol 25
Normalized name: atenolol 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol 25 mg plus lisinopril 5 mg
Study: 6852987
Drug: Atenolol 25
Normalized name: atenolol 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol 25 mg
Study: 8877596
Drug: Lisinopril 5
Normalized name: lisinopril 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril 5 mg
Study: 16258445
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of chemotherapy and radiation
Study: 9418187
Drug: Paternal lymphocyte
Normalized name: Therapeutic allogeneic lymphocytes
DrugBank: Therapeutic allogeneic lymphocytes (DB17459)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paternal lymphocyte immunotherapy (control group).
Study: 26428322
Drug: Daily CSF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily CSF output threshold of 78 mL
Study: 23275415
Drug: Multiple oppositions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple oppositions approach (once weekly for 24 weeks)
Study: 10554799
Drug: Fluconazole (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole (100 mg)
Study: 2059298
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (low-dose cyclosporin A, low-dose methylprednisolone, azathioprine)
Study: 2059298
Drug: Aza and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aza and CyA (double drug treatment)
Study: 2059298
Drug: Aza and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aza and MP (double drug treatment)
Study: 28069480
Drug: Vaginal misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vaginal misoprostol (400 μg)
Study: 8548054
Drug: Melatonin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin (100 mg)
Study: 18561728
Drug: Oral ibuprofen
Normalized name: ibuprofen Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ibuprofen (1 x 10 mg/kg, then 2 x 5 mg/kg at 24‐hour intervals)
Study: 18561728
Drug: Oral indomethacin
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral indomethacin (3 x 0.2 mg/kg at 24‐hour intervals)
Study: 17605699
Drug: Educational Quality
Normalized name: DIABETES PATIENT EDUCATION PACK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Educational Quality Use of Medicines program (academic detailing, prescribing information, feedback, medication risk assessment, medication review facilitation, financial incentives)
Study: 17605699
Drug: Educational Quality
Normalized name: DIABETES PATIENT EDUCATION PACK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Educational Quality Use of Medicines program
Study: 11111068
Drug: 0.3 mg
Normalized name: biotin 0.3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg per hour sustained-release polymer vaginal prostaglandin E(2) insert
Study: 3486546
Drug: Naloxone (0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (0.8 mg, 2 ml) injected i.v. after arm exercise
Study: 29900538
Drug: HMW adiponectin
Approvals — FDA: no, EMA: no, PMDA: no
Description: HMW adiponectin <1.53 μg/mL
Study: 22231540
Drug: Balneotherapy (hot
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balneotherapy (hot spring immersion at 40°C for 10 min daily for 2 weeks)
Study: 22231540
Drug: Control (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (daily shower)
Study: 19633594
Drug: Closed safe
Normalized name: Safe-Guard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Closed safe intravenous system (COSMOS - Compact Closed System)
Study: 15967695
Drug: Intranasal saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal saline challenge
Study: 7679885
Drug: Cold therapy
Normalized name: Deep Cold Therapy
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold therapy (Hot/Ice Thermal Blanket) applied to 13 patients
Study: 18044260
Drug: Pioglitazone (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone (30 mg) plus voglibose
Study: 9621668
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose fentanyl anesthesia (100 micrograms.kg‐1)
Study: 29996082
Drug: H4:IC31 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: H4:IC31 vaccine
Study: 25447444
Drug: Lidocaine infusion
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine infusion 2 mg/kg/h after bolus 1.5 mg/kg
Study: 25447444
Drug: Combined infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combined infusion of lidocaine and dexmedetomidine
Study: 20224901
Drug: SEIQoL-DW intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SEIQoL-DW intervention administered 3-5 times per patient
Study: 1325831
Drug: Nitrendipine 20
Normalized name: nitrendipine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrendipine 20 mg o.d.
Study: 26428409
Drug: Palifermin, 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palifermin, 60 μg/kg, intravenously as a single dose 3 days before and 0, +1, and +2 post autologous HSCT infusion
Study: 19462314
Drug: Candesartan-HCT combination
Normalized name: candesartan / hydrochlorothiazide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan-HCT combination therapy (candesartan 2-32 mg and HCT 6.25-25 mg)
Study: 10072988
Drug: qi-gong therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: qi-gong therapy (group b: 12 GYSK cases, group c: 19 YXYK cases)
Study: 10072988
Drug: nifedipine therapy
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: nifedipine therapy (group d)
Study: 7129331
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg nifedipine
Study: 17616556
Drug: Celecoxib 200
Normalized name: celecoxib 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib 200 mg once a day
Study: 16221219
Drug: Celecoxib 200
Normalized name: celecoxib 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib 200 mg twice a day
Study: 18434566
Drug: Diclofenac 75
Normalized name: CAPSAICIN 0.025%/DICLOFENAC 75MG KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac 75 mg twice a day
Study: 31215676
Drug: Oral amoxicillin
Normalized name: amoxicillin Oral Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral amoxicillin tablets (875 mg)
Study: 31215676
Drug: Oral amoxicillin
Normalized name: amoxicillin Oral Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral amoxicillin suspension (800 mg)
Study: 28532232
Drug: Mixed hydro-alcoholic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixed hydro-alcoholic solution of P. alkekengi, E. amoenum and V. odorata extracts (1.5, 1 and 1.5% respectively)
Study: 16946176
Drug: T(3) augmentation
Normalized name: levothyroxine sodium 0.3 MG [Levo-T]
Approvals — FDA: no, EMA: no, PMDA: no
Description: T(3) augmentation (up to 50 mug/day; N=73)
Study: 31820605
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of paclitaxel liposome and cisplatin
Study: 21247651
Drug: 3% solution
Normalized name: Proxacol 3% Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3% solution of tannin rich plant extracts (AS-21) applied topically for 6 weeks
Study: 28258664
Drug: Patient-controlled intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-controlled intravenous analgesia (group P)
Study: 10755669
Drug: Individual psychotherapy
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individual psychotherapy in combination with antipsychotic medications
Study: 8864420
Drug: Loxiglumide (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loxiglumide (10 mg kg-1 h-1)
Study: 1847977
Drug: Combined chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined chemotherapy and radiotherapy (group B)
Study: 6679507
Drug: Intravenous labetalol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous labetalol (1-2 mg/kg; mean dose 86.5 mg)